@article{fdi:010079091,
  title = {{C}oalition : advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against {COVID}-19},
  author = {{P}icot, {S}. and {M}arty, {A}. and {B}ienvenu, {A}. {L}. and {B}lumberg, {L}. {H}. and {D}upouy-{C}amet, {J}. and {C}arnevale, {P}ierre and {K}ano, {S}. and {J}ones, {M}. {K}. and {D}aniel-{R}ibeiro, {C}. {T}. and {M}as-{C}oma, {S}.},
  editor = {},
  language = {{ENG}},
  abstract = {{O}ur coalition of public health experts, doctors, and scientists worldwide want to draw attention to the need for high-quality evaluation protocols of the potential beneficial effect of hydroxychloroquine ({HCQ}) as a post-exposure drug for exposed people. {I}n the absence of an approved, recognized effective pre or post-exposure prophylactic drug or vaccine for {COVID}-19, nor of any approved and validated therapeutic drug, coupled with social and political pressure raised by publicity both regarding the potential beneficial effect of hydroxychloroquine ({HCQ}) as well as potential risks from {HCQ}, we urge the immediate proper clinical trials. {S}pecifically, we mean using {HCQ} for post-exposure of people with close contact with patients with positive {COVID}19 rt{PCR}, including home and medical caregivers. {W}e have reviewed the mechanisms of antiviral effect of {HCQ}, the risk-benefit ratio taking into consideration the {PK}/{PD} of {HCQ} and the thresholds of efficacy. {W}e have studied its use as an antimalarial, an antiviral, and an immunomodulating drug and concluded that the use of {HCQ} at doses matching that of the standard treatment of {S}ystemic {L}upus erythematous, which has proven safety and efficacy in terms of {HCQ} blood and tissue concentration adapted to bodyweight (2,3), at 6 mg/kg/day 1 (loading dose) followed by 5 mg/kg/ day, with a maximum limit of 600 mg/day in all cases should swiftly be clinically evaluated as a postexposure drug for exposed people.},
  keywords = {{COVID}19 ; {SARS}-{C}o{V}2 ; {H}ydroxychloroquine ; {C}hloroquine ; {S}ystemic lupus erythematosus ; {I}mmunomodulation ; {C}oronavirus, malaria, antiviral},
  booktitle = {},
  journal = {{O}ne {H}ealth},
  volume = {9},
  numero = {},
  pages = {art. 100131 [5 ]},
  year = {2020},
  DOI = {10.1016/j.onehlt.2020.100131},
  URL = {https://www.documentation.ird.fr/hor/fdi:010079091},
}